Reaction Details |
| Report a problem with these data |
Target | Neuromedin-K receptor |
---|
Ligand | BDBM251909 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | Competitive Binding Assay |
---|
Ki | 4.00±n/a nM |
---|
Citation | Hoveyda, HR; Dutheuil, G; Fraser, GL; Roy, M; Bousmaqui, ME; Batt, F Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof US Patent US10683295 Publication Date 6/16/2020 |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Neuromedin-K receptor |
---|
Name: | Neuromedin-K receptor |
Synonyms: | NK-3 receptor | NK-3R | NK3R | NK3R_HUMAN | NKR | Neurokinin 3 receptor | Neurokinin B receptor | Neurokinin-3 (NK-3) | Neuromedin-3 receptor (NK-3R) | Neuromedin-3 receptor (NK3) | Neuromedin-K receptor | Neuromedin-K receptor (NK-3 receptor) | Neuromedin-K receptor (NK3) | Neuromedin-K receptor(NK3R) | TAC3R | TACR3 | Tachykinin receptor 3 | Tachykinin receptor 3 (NK3) |
Type: | Enzyme |
Mol. Mass.: | 52221.96 |
Organism: | Homo sapiens (Human) |
Description: | P29371 |
Residue: | 465 |
Sequence: | MATLPAAETWIDGGGGVGADAVNLTASLAAGAATGAVETGWLQLLDQAGNLSSSPSALGL
PVASPAPSQPWANLTNQFVQPSWRIALWSLAYGVVVAVAVLGNLIVIWIILAHKRMRTVT
NYFLVNLAFSDASMAAFNTLVNFIYALHSEWYFGANYCRFQNFFPITAVFASIYSMTAIA
VDRYMAIIDPLKPRLSATATKIVIGSIWILAFLLAFPQCLYSKTKVMPGRTLCFVQWPEG
PKQHFTYHIIVIILVYCFPLLIMGITYTIVGITLWGGEIPGDTCDKYHEQLKAKRKVVKM
MIIVVMTFAICWLPYHIYFILTAIYQQLNRWKYIQQVYLASFWLAMSSTMYNPIIYCCLN
KRFRAGFKRAFRWCPFIKVSSYDELELKTTRFHPNRQSSMYTVTRMESMTVVFDPNDADT
TRSSRKKRATPRDPSFNGCSRRNSKSASATSSFISSPYTSVDEYS
|
|
|
BDBM251909 |
---|
n/a |
---|
Name | BDBM251909 |
Synonyms: | US10065961, Compound 7 | US10683295, Compound 7 | US10941151, Compound 7 | US9475814, 7 |
Type | Small organic molecule |
Emp. Form. | C22H19N5OS2 |
Mol. Mass. | 433.549 |
SMILES | C[C@H]1N(CCn2c1nnc2-c1csc(C=C)n1)C(=O)c1ccc(cc1)-c1cccs1 |r| |
Structure |
|